{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T05:49:09Z","timestamp":1773985749906,"version":"3.50.1"},"reference-count":16,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T00:00:00Z","timestamp":1514332800000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>With the advent of effective antivirals against cytomegalovirus (<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>), use of <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> hyperimmune globulin (HIG) has decreased. Although antiviral prophylaxis in patients at high risk for <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> is effective, many patients still have late infection, never developing antibodies sufficient to achieve immunity. Utilizing a combination of antiviral and <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> HIG may allow patients to achieve immunity and decrease late <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a prospective randomized, open\u2010label, pilot study comparing valganciclovir (<jats:styled-content style=\"fixed-case\">VGCV<\/jats:styled-content>) prophylaxis for 200\u00a0days vs <jats:styled-content style=\"fixed-case\">VGCV<\/jats:styled-content> for 100\u00a0days followed by <jats:styled-content style=\"fixed-case\">CMV HIG<\/jats:styled-content> in abdominal transplant recipients at high risk for <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>. The primary outcome was a comparison of late <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty patients were randomized to <jats:styled-content style=\"fixed-case\">VGCV<\/jats:styled-content> for 200\u00a0days (n\u00a0=\u00a020) or <jats:styled-content style=\"fixed-case\">VGCV<\/jats:styled-content> for 100\u00a0days followed by 3 doses of monthly <jats:styled-content style=\"fixed-case\">CMV HIG<\/jats:styled-content> (n\u00a0=\u00a020). Numerically, more overall <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> infections occurred in the <jats:styled-content style=\"fixed-case\">CMV HIG<\/jats:styled-content> group (45 vs 20%, <jats:italic>P<\/jats:italic>\u00a0=\u00a0.09). No differences in overall <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> infections or late <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> disease were seen between groups (20% vs 15%, <jats:italic>P<\/jats:italic>\u00a0=\u00a01.00 and 0 vs 0, <jats:italic>P<\/jats:italic>\u00a0=\u00a01.00). All <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> disease occurred within 200\u00a0days, with 63% occurring while patients were on <jats:styled-content style=\"fixed-case\">VGCV<\/jats:styled-content>. No differences were found in toxicities, graft function, or rejection between groups. Patients with <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> infection at any time had a higher body weight than those who did not have an infection (82 vs 95\u00a0kg, <jats:italic>P<\/jats:italic>\u00a0=\u00a0.049).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Use of <jats:styled-content style=\"fixed-case\">CMV HIG<\/jats:styled-content> sequentially with prophylaxis may be an effective and affordable prophylactic regimen in abdominal transplant recipients at high risk for <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>, and warrants larger prospective study. Increased monitoring for patients with obesity may be warranted.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.12779","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T14:10:26Z","timestamp":1505743826000},"source":"Crossref","is-referenced-by-count":6,"title":["Valganciclovir (<scp>VGCV<\/scp>) followed by cytomegalovirus (<scp>CMV<\/scp>) hyperimmune globulin compared to <scp>VGCV<\/scp> for 200\u00a0days in abdominal organ transplant recipients at high risk for <scp>CMV<\/scp> infection: A prospective, randomized pilot study"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9686-3107","authenticated-orcid":false,"given":"James N.","family":"Fleming","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services Medical University of South Carolina  Charleston SC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7273-4589","authenticated-orcid":false,"given":"David J.","family":"Taber","sequence":"additional","affiliation":[{"name":"Department of Surgery Medical University of South Carolina  Charleston SC USA"},{"name":"Department of Pharmacy Ralph H Johnson VAMC  Charleston SC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole A.","family":"Weimert","sequence":"additional","affiliation":[{"name":"Division of Transplant Medical University of South Carolina  Charleston SC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satish","family":"Nadig","sequence":"additional","affiliation":[{"name":"Department of Surgery Medical University of South Carolina  Charleston SC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"McGillicuddy","sequence":"additional","affiliation":[{"name":"Department of Surgery Medical University of South Carolina  Charleston SC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles F.","family":"Bratton","sequence":"additional","affiliation":[{"name":"Department of Surgery Medical University of South Carolina  Charleston SC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhakar K.","family":"Baliga","sequence":"additional","affiliation":[{"name":"Department of Surgery Medical University of South Carolina  Charleston SC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth D.","family":"Chavin","sequence":"additional","affiliation":[{"name":"Hepatobiliary and Transplant Surgery Transplant Institute University Hospitals Cleveland Medical Center  Cleveland OH USA"},{"name":"Department of Surgery Case Western Reserve University School of Medicine  Cleveland OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,12,27]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01781.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01413.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2006.00639.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2009.00372.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000090163.48433.48"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.02133.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.2001.00008.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181ff1493"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03074.x"},{"key":"e_1_2_6_11_1","unstructured":"Valcyte [package insert].South San Francisco CA:Genentech;2015."},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.1.3.401"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198710223171703"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.00299.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250328"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-4-200608150-00004"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00382.x"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12779","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12779","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T03:07:36Z","timestamp":1696043256000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/tid.12779"],"URL":"https:\/\/doi.org\/10.1111\/tid.12779","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"e12779"}}